Arcus Biosciences, Inc. (NYSERCUS), a clinical-stage, global biopharmaceutical company focused on developing differentiated molecules and combination therapies for people with cancer, today announced that the Compensation Committee of the Company’s Board of Directors granted four new employees options to purchase a total of 31,800 shares of the Company’s common stock at an exercise price per share of $13.33, which was the closing price on January 23, 2024, and restricted stock units to acquire a total of 16,000 shares of the Company’s common stock. The equity awards were granted pursuant to the Company’s 2020 Inducement Plan, which was approved by the Company’s Board of Directors in January 2020 pursuant to the “inducement exception” under NYSE Listed Company Manual Rule 303A.08.

Arcus Biosciences, Inc. (NYSERCUS), a clinical-stage, global biopharmaceutical company focused on developing differentiated molecules and combination therapies for people with cancer, today announced that Richard Markus, M.D., Ph.D., has been appointed chief medical officer (CMO) effective January 31, 2025. Dr. Markus replaces Dimitry Nuyten, M.D., Ph.D., who will be leaving the company at the end of January to pursue other opportunities. Dr. Markus’s responsibilities will include oversight of Arcus’s clinical development organization and its late-stage portfolio, currently including four ongoing registrational Phase 3 studies, the first of which, STAR-221, is expected to read out next year. Arcus plans to initiate a fifth registrational Phase 3 study, PEAK-1, in the first half of 2025, to evaluate its HIF-2a inhibitor casdatifan plus cabozantinib in people with clear-cell renal cell carcinoma (ccRCC) who have progressed on immunotherapy. Dr. Markus’s extensive late-stage development experience will be essential as he leads Arcus’s strategy and efforts to fully leverage the opportunities in Arcus’s portfolio.

Arcus Biosciences, Inc. (NYSERCUS), a clinical-stage, global biopharmaceutical company focused on developing differentiated molecules and combination therapies for patients with cancer, today announced that the Compensation Committee of the Company’s Board of Directors granted four new employees options to purchase a total of 66,900 shares of the Company’s common stock at an exercise price per share of $15.96, which was the closing price on December 23, 2024, and restricted stock units to acquire a total of 33,450 shares of the Company’s common stock. The equity awards were granted pursuant to the Company’s 2020 Inducement Plan, which was approved by the Company’s Board of Directors in January 2020 pursuant to the “inducement exception” under NYSE Listed Company Manual Rule 303A.08.

Arcus Biosciences (NYSERCUS), a clinical-stage, global biopharmaceutical company focused on developing differentiated molecules and combination therapies for patients with cancer, announced that Terry Rosen, Ph.D., chief executive officer, will present at the upcoming 43rd Annual J.P. Morgan Healthcare Conference in San Francisco, CA. The presentation will take place on Tuesday, January 14th, 2025, at 3:45pm PT.

Arcus Biosciences, Inc. (NYSERCUS), a clinical-stage, global biopharmaceutical company focused on developing differentiated molecules and combination therapies for patients with cancer, today announced that the Compensation Committee of the Company’s Board of Directors granted two new employees options to purchase a total of 7,400 shares of the Company’s common stock at an exercise price per share of $17.47 which was the closing price on December 9, 2024, and restricted stock units to acquire a total of 3,700 shares of the Company’s common stock. The equity awards were granted pursuant to the Company’s 2020 Inducement Plan, which was approved by the Company’s Board of Directors in January 2020 pursuant to the “inducement exception” under NYSE Listed Company Manual Rule 303A.08.

Arcus Biosciences, Inc. (NYSERCUS), a clinical-stage, global biopharmaceutical company focused on developing differentiated molecules and combination therapies for patients with cancer, today announced that the Compensation Committee of the Company’s Board of Directors granted three new employees options to purchase a total of 10,000 shares of the Company’s common stock at an exercise price per share of $14.56, which was the closing price on November 25, 2024, and restricted stock units to acquire a total of 5,000 shares of the Company’s common stock. The equity awards were granted pursuant to the Company’s 2020 Inducement Plan, which was approved by the Company’s Board of Directors in January 2020 pursuant to the “inducement exception” under NYSE Listed Company Manual Rule 303A.08.

Arcus Biosciences (NYSERCUS), a clinical-stage, global biopharmaceutical company focused on developing differentiated molecules and combination therapies for patients with cancer, announced that its management team will participate in the following upcoming investor conferences in December:

Arcus Biosciences, Inc. (NYSERCUS), a clinical-stage, global biopharmaceutical company focused on developing differentiated molecules and combination therapies for people with cancer, today announced that the Compensation Committee of the Company’s Board of Directors granted four new employees options to purchase a total of 14,100 shares of the Company’s common stock at an exercise price per share of $17.85, which was the closing price on November 8, 2024, and restricted stock units to acquire a total of 7,050 shares of the Company’s common stock. The equity awards were granted pursuant to the Company’s 2020 Inducement Plan, which was approved by the Company’s Board of Directors in January 2020 pursuant to the “inducement exception” under NYSE Listed Company Manual Rule 303A.08.

Arcus Biosciences, Inc. (NYSERCUS), a clinical-stage, global biopharmaceutical company focused on developing differentiated molecules and combination therapies for patients with cancer, today reported financial results for the third quarter ended September 30, 2024, and provided a pipeline update on its clinical-stage investigational molecules — targeting TIGIT, HIF-2a, CD73, the A2a/A2b receptors, CD-39, AXL and PD-1 — across multiple common cancers.

Arcus Biosciences, Inc. (NYSERCUS), a clinical-stage, global biopharmaceutical company focused on developing differentiated molecules and combination therapies for patients with cancer, today announced results from Part 1 of ARC-10, a randomized, open-label, three-arm study evaluating domvanalimab, an Fc-silent anti-TIGIT monoclonal antibody, plus zimberelimab, an anti-PD-1 monoclonal antibody, (DZ) versus zimberelimab (Z) or chemotherapy in patients with front-line locally advanced or metastatic squamous or non-squamous non-small cell lung cancer (NSCLC) with PD-L1 tumor proportion score (TPS) ≥50% without the presence of any tumor genomic aberration or driver mutation for which a targeted therapy is approved. This study was conducted in partnership with Gilead Sciences. These results will be presented on November 8 in a late-breaking poster session at the Society for Immunotherapy of Cancer (SITC) 2024 Annual Meeting by Melissa L. Johnson, M.D., Director of the Lung Cancer Research Program, Sarah Cannon Research Institute, and investigator for the ARC-10 study.

Arcus Biosciences, Inc. (NYSERCUS), a clinical-stage, global biopharmaceutical company focused on developing differentiated molecules and combination therapies for patients with cancer, today announced four accepted abstracts at the Society for Immunotherapy of Cancer (SITC) Annual Meeting, taking place in Houston, Texas, November 6 – 10, 2024.

Arcus Biosciences, Inc. (NYSERCUS), a clinical-stage, global biopharmaceutical company focused on developing differentiated molecules and combination therapies for people with cancer, today announced that the Compensation Committee of the Company’s Board of Directors granted six new employees options to purchase a total of 28,600 shares of the Company’s common stock at an exercise price per share of $17.33, which was the closing price on October 23, 2024, and restricted stock units to acquire a total of 14,300 shares of the Company’s common stock. The equity awards were granted pursuant to the Company’s 2020 Inducement Plan, which was approved by the Company’s Board of Directors in January 2020 pursuant to the “inducement exception” under NYSE Listed Company Manual Rule 303A.08.

Arcus Biosciences, Inc. (NYSERCUS), a clinical-stage, global biopharmaceutical company focused on developing differentiated molecules and combination therapies for patients with cancer, today presented the first clinical activity data for casdatifan, a HIF-2a inhibitor with best-in-class potential, in an oral plenary session by Dr. Toni K. Choueiri, Dana-Farber Cancer Institute at the 2024 EORTC-NCI-AACR Symposium on Molecular Targets and Cancer Therapeutics in Barcelona, Spain.

Arcus Biosciences (NYSERCUS), a clinical-stage, global biopharmaceutical company focused on developing differentiated molecules and combination therapies for patients with cancer, announced that its management team will host a conference call and webcast on Wednesday, November 6th, 2024 at 2 PM PT / 5 PM ET to discuss details of the Company’s financial results and pipeline update for the quarter ended September 30th, 2024.

Arcus Biosciences, Inc. (NYSERCUS), a clinical-stage, global biopharmaceutical company focused on developing differentiated molecules and combination therapies for people with cancer, today announced that the Compensation Committee of the Company’s Board of Directors granted four new employees options to purchase a total of 24,100 shares of the Company’s common stock at an exercise price per share of $17.47, which was the closing price on October 8, 2024, and restricted stock units to acquire a total of 12,050 shares of the Company’s common stock. The equity awards were granted pursuant to the Company’s 2020 Inducement Plan, which was approved by the Company’s Board of Directors in January 2020 pursuant to the “inducement exception” under NYSE Listed Company Manual Rule 303A.08.

Arcus Biosciences, Inc. (NYSERCUS), a clinical-stage, global biopharmaceutical company focused on developing differentiated molecules and combination therapies for people with cancer, today announced four accepted abstracts at the 2024 EORTC-NCI-AACR Symposium on Molecular Targets and Cancer Therapeutics being held October 23-25, 2024, in Barcelona, Spain. The data being presented include a growing body of evidence supporting the potential of casdatifan as a best-in-class HIF-2a inhibitor for the treatment of ccRCC.

Arcus Biosciences, Inc. (NYSERCUS), a clinical-stage, global biopharmaceutical company focused on developing differentiated molecules and combination therapies for people with cancer, today announced a clinical trial collaboration agreement with AstraZeneca (LSE/STO/Nasdaq: AZN) to evaluate casdatifan (AB521), Arcus’s investigational HIF-2a inhibitor, in combination with volrustomig, AstraZeneca’s investigational PD-1/CTLA-4 bispecific antibody, in patients with ccRCC.